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Lichen Planus Induced by Interferon-a-2B Therapy in a Patient with Cutaneous Malignant
Melanoma
Sir,
Interferons (IFNs) are cytokines widely used in medicine for
their antiproliferative, antiviral and immunomodulatory
effects. Their most common side effect is an influenza-like
syndrome characterized by fever, headache and muscle pain.
Also, IFNs infrequently induce or worsen some dermatoses,
such as herpes labialis, psoriasis, pemphigus and vitiligo (1).
Several papers have referred to the induction or exacerbation
of lichen planus (LP) in patients treated with IFN for
hepatitis C virus (HCV) infection (2, 3). LP has, however,
rarely been described in patients treated with IFN without
HCV infection or in patients with melanoma treated with
IFN. We describe here a patient with a cutaneous malignant
melanoma, stage III, HCV negative, who developed a
mucocutaneous lichen planus after 3 months of therapy
with recombinant IFN-a-2b.
CASE REPORT
A 51-year-old male had a nodular melanoma on his back (Breslow 3.5
mm, Clark V) that was removed in 1994 with local recurrence 2 years
later. A wide local excision was performed and the defect was closed
with a full thickness skin graft. Lymph node metastases on the right
axilla were detected in April 1997 (Stage III disease -N2a- of the
American Joint Committee on Cancer) and a therapeutic node
disection was performed. One month later, the patient started therapy
with intravenous IFN-a-2b (Intron1) at 106 U/day for the first
month, followed by subcutaneous IFN 106 U, 3 times a week, being
well tolerated.
After 3 months of therapy the patient developed generalized,
pruriginous, erythematous papules located on the wrist, forearms and
dorsa of the feet. There were also reticulated, not ulcerated, white
plaques on buccal and genital mucosae. The results of the following
studies were within normal limits or negative: blood cell count, liver
function test, urinalysis and serology for HCV, HBV, Epstein Barr
virus and cytomegalovirus. CT scans of the thorax and abdomen were
normal without recurrence of melanoma. The biopsies from the skin
and oral mucosa revealed irregular acantosis, basal vacuolation and a
dense band-like lymphohistiocytic infiltrate. We diagnosed LP
eruption induced by IFN-a-2b. Oral administration of deflazacort,
30 mg/day, was started and therapy with IFN was continued. One
month later, the skin lesions improved and deflazacort dosage was
gradually reduced and discontinued. After 12 months, therapy with
IFN was discontinued although a few new asymptomatic lesions of
LP appeared, but no further treatment was required.
DISCUSSION
In the last few years, an increased prevalence of HCV
infection (subtype 1b) has been reported in patients with LP,
mainly with the erosive oral type, ranging from 14% to 26%.
The prevalence of LP in patients with HCV is around 5.5%
and it would increase until 16.7% in patients treated with IFN
(3, 4). Induction of LP and exacerbation of pre-existing
lesions have been reported in patients with HCV infection
treated with IFN (4). Nevertheless, several cases of LP have
improved or cured with IFN therapy (5). These effects do not
depend on dose or on the type of IFN used. In a few cases
who got worse it was necessary to discontinue the treatment
(2, 5).
The pathogenetic mechanisms by which IFN would induce
or exacerbate LP remain unknown. Some papers have
demonstrated that IFN-a increases IFN-c level, which has
a great pro-inflammatory activity.
The appearance of LP in patients without HCV infection
treated with IFN has previously been referred in 3 cases with
lymphoproliferative disorders, but never in patients with
melanoma, in spite of the increasing use of IFN in melanoma
(6 – 8). We believe that in the case described here the presence
of an advanced malignant melanoma influenced the develop-
ment of LP after IFN therapy, due to the fact that these
patients have diverse alterations in the recognition of tumoral
antigens.
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